VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IMVT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IMVTImmunovant, Inc.
$33.21$6.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. IMVT
  4. Financial Ratios

Immunovant, Inc. (IMVT) Financial Ratios

Latest Ratios: P/E Ratio -13.5x · EV/EBITDA N/A · ROE -64.8%. (2018–2026 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

IMVT Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$6.9B$4.5B$2.6B$4.5B$1.9B$604M$1.4B$673M——
Enterprise Value$6.0B$3.6B$1.9B$3.8B$1.5B$113M$1.0B$575M——
P/E Ratio →-13.49—————————
P/S Ratio966.12—————————
P/B Ratio7.115.313.667.225.271.293.607.15——
P/FCF——————————
P/OCF——————————

P/E links to full P/E history page with 30-year chart

IMVT EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue——————————
EV / EBITDA——————————
EV / EBIT——————————
EV / FCF——————————

IMVT Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin——————————
Operating Margin——————————
Net Profit Margin——————————

Return on Capital

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE-64.8%-64.8%-62.5%-52.9%-50.7%-36.4%-44.3%-141.1%-1.8%—
ROA-58.3%-58.3%-57.4%-48.4%-45.8%-33.8%-41.2%-120.9%-0.2%-120827.1%
ROIC——————————
ROCE-68.3%-68.3%-66.1%-55.1%-50.0%-36.1%-44.3%-126.8%-1.8%—

IMVT Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.000.000.000.000.000.010.010.0312.22—
Debt / EBITDA————————31.41—
Net Debt / Equity—-1.06-1.01-1.03-1.04-1.05-1.01-1.04-1.02—
Net Debt / EBITDA————————-2.62—
Debt / FCF——————————
Interest Coverage————-15.90——-105.07——

Net cash position: cash ($902M) exceeds total debt ($72000)

IMVT Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio9.099.0911.1613.709.3411.5221.797.120.850.07
Quick Ratio9.099.0911.1613.709.3411.5221.797.120.850.07
Cash Ratio8.648.6410.3813.078.7011.0921.326.570.85—
Asset Turnover——————————
Inventory Turnover——————————
Days Sales Outstanding——————————

IMVT Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield——————————
Payout Ratio——————————

Total Shareholder Return Metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield——————————
FCF Yield——————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$182M$152M$138M$123M$110M$88M$43M$14M$10M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Continued cash burn dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2027Q2)

Valuation Reflects Pipeline Optionality Not Earnings

Based on reported figures, IMVT trades at a trailing P/E of -14.23 and a price-to-sales multiple above 1,000, reflecting a market price anchored to pipeline value rather than any current earnings or revenue base that could support conventional comparison.

The negative trailing P/E and absence of forward or EV-based multiples indicate that conventional earnings-based valuation is not meaningful for this pre-revenue company. The 7.50 price-to-book ratio versus a peer range spanning roughly 3.0 to 8.3 suggests the market is paying a premium over book value for the clinical portfolio, which investors may view as embedding a high probability of successful Phase 3 readouts. Valuation therefore appears to hinge on pipeline probability assumptions rather than on observable financial performance, warranting close monitoring of catalyst timing.

Net Margins Deeply Negative Across Quarters

As reported in financial statements, IMVT's operating margin of -21.6% in 2027Q1 and return on equity of -14.0% to -27.7% across recent quarters indicate losses that remain large relative to both revenue and shareholder capital.

With revenue essentially absent in most quarters, margin ratios are structurally distorted and should be read as indicators of cost scale rather than operating efficiency. The 2027Q1 margin profile, where a 100% gross margin sits alongside negative operating and net margins, suggests the fixed R&D base overwhelms any incremental revenue. Operating losses appear driven by development spending, so earning power is better judged through cash burn and pipeline milestones than through margin trends.

Return Metrics Remain Persistently Negative

Based on reported figures, IMVT's ROIC of -26.5% in 2026Q2 and -59.6% in 2026Q1, alongside ROA between -12.1% and -23.7%, show capital being consumed rather than compounded over the ten-quarter window.

Negative ROIC and ROA across the period indicate that invested capital is generating losses rather than returns, a pattern typical of clinical-stage biotechs but one that offers no evidence of decay reversing. The variance between the -59.6% and -26.5% ROIC readings suggests the denominator and loss trajectory are both shifting quarter to quarter. Returns will likely remain negative until a commercial product generates sustained earnings, so investors should treat these ratios as measures of burn intensity.

Ample Liquidity Buffer Masks Burn Rate

As reported in financial statements, IMVT's current ratio of 7.31 in 2027Q2 and 9.09 at year-end 2026 indicate a substantial short-term liquidity cushion, though this buffer shrinks relative to roughly $1.0B of cumulative negative free cash flow.

A current ratio above 7 implies that current liabilities are small relative to liquid assets, supporting near-term solvency without any debt service pressure. However, liquidity ratios capture a point-in-time snapshot and do not reflect the trajectory of cash depletion. Investors should weigh the strong current ratio against the cash balance decline from $902.1M to $722.3M, as the headline cushion may appear more comfortable than the underlying runway warrants.

Debt-Free Balance Sheet Shifts Risk to Equity

According to recent SEC filings, IMVT reported a debt-to-equity ratio of 0.00 in 2026Q4 and 2025Q4 with no interest coverage applicable, meaning the solvency risk is concentrated in equity dilution rather than debt service.

The absence of leverage removes refinancing and covenant exposure, which is a structural strength for a company without commercial revenue. Because losses are eroding shareholders' equity, the zero debt position effectively means future funding will likely come through dilutive equity issuance. The balance sheet therefore appears to trade one form of risk for another, and monitoring of financing announcements is warranted.

Headline Ratios Mislead on Pre-Revenue Economics

Based on reported figures, the 7.31 current ratio and zero debt-to-equity may appear reassuring, but these metrics obscure a cash burn exceeding $1.0B over ten quarters that conventional ratios do not capture.

Ratios like the current ratio and P/E are most commonly misapplied to pre-revenue biotechs because they assume a stable earnings base that does not yet exist. A high current ratio reflects cash on hand, not the duration of that cash against burn, so a more appropriate lens is cash runway measured as cash divided by trailing quarterly free cash flow burn. Investors should also weigh the pipeline's probability-adjusted value against book value, since the 7.50 price-to-book ratio is driven largely by intangible optionality rather than tangible assets.

Download Financial Ratios Data

Includes 30+ ratios · 9 years · Updated daily

Consensus & Technical Research Suite
Open IMVT Terminal

IMVT Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

IMVT — Frequently Asked Questions

Quick answers to the most common questions about buying IMVT stock.

What is Immunovant, Inc.'s P/E ratio?

Immunovant, Inc.'s current P/E ratio is -13.5x. This places it at the 50th percentile of its historical range.

What is Immunovant, Inc.'s ROE?

Immunovant, Inc.'s return on equity (ROE) is -64.8%. The historical average is -56.8%.

Is IMVT stock overvalued?

Based on historical data, Immunovant, Inc. is trading at a P/E of -13.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.